AFN-1252

AFN-1252 is an orally active and selective inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 exhibits exquisite and highly selective activity against Staphylococcus spp. AFN-1252 exhibits typical MIC90 values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus. AFN-1252 is efficacious in a mouse model of septicemia providing 100% protection from an otherwise lethal peritoneal infection of S. aureus Smith[1][2].

Product Specifications

CAS Number

[620175-39-5]

Product Name Alternative

API-1252; Debio 1452

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/AFN-1252.html

Purity

99.49

Solubility

DMSO : 5.8 mg/mL (ultrasonic)

Smiles

O=C(N(C)CC1=C(C)C2=CC=CC=C2O1)/C=C/C(C=C3CC4)=CNC3=NC4=O

Molecular Formula

C22H21N3O3

Molecular Weight

375.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Nachum Kaplan, et al. In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics. J Chemother. 2013 Feb;25 (1) :18-25.|[2]Nachum Kaplan, et al. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob Agents Chemother. 2012 Nov;56 (11) :5865-74.